203 results about "Dose dependence" patented technology

The invention discloses a shell nacre-derived anti-inflammatory active peptide and application thereof in preparation of a skin repair product. The inhibition rate of the active peptide GEIRYEYF provided by the invention on the NO release amount is concentration-dependent, and the NO release amount is reduced by 54.32 + / -2.13% under the concentration of 200 mu g / mL; in addition, secretion of RAW264.7 macrophage pro-inflammatory cytokines TNF-alpha and IL-6 can be remarkably reduced, secretion of anti-inflammatory cytokines IL-10 can be improved, dose dependence is achieved, under the highest concentration, the influence on IL-6 secretion is 47.76 + / -1.02%, the influence on TNF-alpha secretion is 42.01 + / -4.64%, the influence on IL-10 secretion is 41.71 + / -1.67%, and good anti-inflammatory activity is achieved. In addition, the bioactive peptide has a remarkable proliferation effect on L929 cells, and it is indicated that the bioactive peptide has the potential of promoting skin wound healing.

The invention relates to the technical field of biological medicine, in particular to an antibody aiming at staphylococcus aureus enterotoxin B and application thereof. A heavy chain variable region of the antibody provided by the invention comprises CDR sequences as shown in SEQ ID NO.1-3, and a light chain variable region of the antibody comprises CDR sequences as shown in SEQ ID NO.9-11. The antibody has high affinity, can specifically bind to staphylococcus aureus SEB, can block binding of SEB and MHC II / TCR, significantly inhibits cytokine storm, shows a dose-dependent protection effect in an MRSA systemic infection model, and can be used for preparing an MRSA systemic infection model. The monoclonal antibody can be used for treating, preventing or diagnosing the infection of the staphylococcus aureus, provides a solution of non-antibiotic therapy for SEB poisoning and drug-resistant staphylococcus aureus infection, and has important clinical and public health values.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention belongs to the technical field of pest control, discloses a bactrocera dorsalis attractant and application thereof, and particularly discloses application of trans-3-hexenoic acid or pharmaceutically acceptable salt thereof in pest control or preparation of a pest attractant. The invention provides the application of the trans-3-hexenoic acid or the pharmaceutically acceptable salt thereof in pest control or preparation of the pest attractant for the first time, and experiments prove that the trans-3-hexenoic acid has a relatively good attraction effect on bactrocera dorsalis and presents a certain degree of dose dependence.

The invention discloses application of phenazine-1-carboxylic acid or medicinal salt thereof in preparation of drugs for inhibiting African swine fever virus. According to the invention, a double-report virus rASFV-Glucc / EGFP for co-expressing green fluorescent protein and Gaussian luciferase is used, and screening from 246 natural small molecule compounds finds that phenazine-1-carboxylic acid has a remarkable inhibition effect on the replication of ASFV; the inhibition effect of the PCA is further evaluated, and it is found that the half maximum cytotoxicity concentration of the PCA to primary porcine alveolar macrophages of target cells is 470.5 mu M, and the half maximum inhibition concentration of the PCA to ASFV in PAMs is 1.59 mu M. According to a dose-dependent inhibition experiment result, when the PCA concentration is 25 [mu] M, the ASFV inhibition effect can reach 100 times or more. The invention has application prospects in preparation of anti-ASFV drugs or preparations and the like.

The invention belongs to the technical field of fish disease prevention and treatment, and particularly relates to application of chlorogenic acid in preparation of a product for preventing and treating GCHV viral inflammation. The regulation and control effects of chlorogenic acids with different concentrations (0.1%, 0.5% and 1%) on inflammatory factors (TNF-alpha, IL-1beta and IL-16) infected by the GCRV II virus are systematically analyzed, and the condition that the expression of the inflammatory factors (TNF-alpha, IL-1beta and IL-16) is obviously inhibited from the third day to the seventh day after infection by 0.5% chlorogenic acid is found; 0.01), the effect of which is not statistically different from that of the blank group (CK) (pgt; 0.05) of the method. If the high-concentration group has proinflammatory effect inversion (IL-1beta superscript 15.4%, p = 0.031) on the ninth day, dose-dependent toxicity is prompted. Results show that 0.5% chlorogenic acid can effectively inhibit viral inflammatory response, and long-term use of high dosage of chlorogenic acid may cause immune disorder.

The invention discloses application of eleutheroside E in preparation of a medicine for preventing or treating hepatic fibrosis, and belongs to the technical field of biological medicine. The chemical name of the eleutheroside E is 4-[(1R, 3aS, 4S, 6aR)-4-[4-(beta-D-glucoside oxygen group)-3, 5-dimethoxy phenyl] tetrahydro-1H, 3H-furo [3, 4-c] furan-1-yl]-2, 6-dimethoxy phenyl-beta-D-glucoside, and the molecular formula of the eleutheroside E is C34H46O18. Researches find that the eleutheroside E has a remarkable effect of preventing or treating hepatic fibrosis diseases, does not have remarkable hepatotoxicity, and can be used for preparing the medicine for preventing or treating hepatic fibrosis. Cell experiment results show that the eleutheroside E can significantly reduce the proliferation activity of mouse hepatic stellate cells JS-1 and inhibit hepatic stellate cell activation, presents dose dependence and can be used for preparing the medicine for preventing or treating hepatic fibrosis.

The invention relates to application of mesenchymal stem cells of overexpressed Numb genes in preparation of drugs for treating chronic liver diseases. The invention also provides a mesenchymal stem cell modified by genetic engineering, and the mesenchymal stem cell modified by genetic engineering is a mesenchymal stem cell of an overexpressed Numb gene. The invention provides a novel human umbilical cord mesenchymal stem cell (hUC-MSC) for treating chronic and acute hepatic failure, hepatic fibrosis and liver cirrhosis. The hUC-MSCs overexpressing the Numb gene can inhibit liver inflammatory response and hepatic fibrosis progress in a dose-dependent manner; biliary duct reaction is inhibited in a dose-dependent manner, and cholestasis is improved; the liver cell proliferation can be promoted in a dose-dependent manner, and the content of serum albumin is increased. And the treatment effects are better than those of the same dose of hUC-MSCs. The hUC-MSCsNumb-OE can be directly used as a cell for treating chronic and acute hepatic failure, hepatic fibrosis and cirrhosis, and also can be used as a tool for screening biological or chemical medicines for treating hepatic fibrosis and cirrhosis.

The invention discloses a novel immunologic adjuvant, a composition containing the immunologic adjuvant and a pharmaceutical composition. The immunologic adjuvant is picrasidine S. The immunologic adjuvant composition comprises picrasidine S and optionally one or more other types of immunologic adjuvants, such as an aluminum adjuvant. The pharmaceutical composition comprises an antigen and the immunologic adjuvant composition. Experiments prove that the picrasidine S can effectively stimulate dendritic cells to generate cell factors IFN-beta and IL-6, and has PS dose dependence; picrasidine S plays an important role in enhancing specific humoral immune response of different types of antigens, and has a stronger effect than an aluminum adjuvant; the picrasidine S immunity can enhance the anti-tumor immune response in different tumor models. According to the invention, a new candidate drug is provided for research and development of a new generation of vaccine adjuvants, and meanwhile, the medical application of the picrasidine S is also widened.

The invention discloses a formula for reducing phlegm and resolving masses, and a preparation method and application of freeze-dried powder of the formula for reducing phlegm and resolving masses, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition inhibits triple negative breast cancer adhesion-metastasis by regulating an FAK / SRC pathway, and comprises the following components by weight: 10-20 g of poria cocos, 10-20 g of rhizoma bolbostemmae, 10-20 g of radix trichosanthis, 5-12 g of curcuma zedoary, 10-20 g of selfheal, 10-20 g of oyster (smashed and decocted first), and 5-12 g of uniflower swisscentaury root. In-vitro experiments show that HTSJF can inhibit TNBC cell invasion, migration and adhesion (P is less than 0.01) in a dose-dependent manner, and along with reduction of the phosphorylation level of an FAK / SRC pathway, it is prompted that HTSJF inhibits TNBC transfer by regulating the pathway. In-vivo experiments prove that the HTSJF can obviously inhibit the reduction of TNBC pulmonary metastasis focus (P is less than 0.05) and recover part of normal pulmonary alveolar structures, and the inhibition effect of the HTSJF on TNBC pulmonary metastasis is further proved.

The invention relates to an application of Avasimibe in preparation of a medicine for treating nasopharynx cancer or oral cancer, and belongs to the field of tumor targeted therapy. An in-vitro cell experiment and an in-vivo animal model experiment verify the anti-tumor effect of the compound. Experiments show that Avasimibe can significantly inhibit the activity, proliferation ability, healing ability and cloning ability of nasopharynx cancer cells and oral cancer cells, can regulate cell cycle arrest in a dose-dependent manner, and induces cell apoptosis. In vivo experiments, the tumor volume of nude mice in an Avasimibe treatment group is remarkably reduced, serum cholesterol is remarkably reduced, and serum biochemical analysis shows that compared with a control group, the Avasimibe treatment group has no statistical difference in indexes such as aspartate transaminase (AST) / glutamic-pyruvic transaminase (ALT) and creatinine (Cr). The invention provides a new indication for resisting nasopharynx cancer and oral cancer for the existing compound Avassimibe, has the clinical advantages of low toxicity and capability of overcoming drug resistance, and provides a new treatment choice for patients with nasopharynx cancer and oral cancer.

The invention discloses an application of DL-3-phenyllactic acid in treatment of cardiac mucinoma. Based on metabonomics, it is found that the level of endogenous DL-3-phenyllactic acid in serum of a patient is remarkably reduced, pharmacodynamic verification is conducted by means of a cardiac mucinoma tissue-derived cardiac mucinoma organ model of the patient, it is proved that DL-3-phenyllactic acid can inhibit proliferation of cardiac mucinoma organs in a dose-dependent mode, and the half inhibitory concentration IC50 value of DL-3-phenyllactic acid is 95.52 mu M. The DL-3-phenyllactic acid can inhibit proliferation of cardiac mucinoma organs in a dose-dependent mode. Network pharmacological analysis indicates that the drug action mechanism may involve key targets such as AKT1 and SRC. The invention discloses the therapeutic efficacy of the DL-3-phenyllactic acid on the cardiac mucinoma for the first time, and provides a solid preclinical experimental basis for developing the DL-3-phenyllactic acid into the medicine for treating the cardiac mucinoma. The invention has non-obvious and important clinical application value.

The invention relates to application of amlexanox and polydatin in preparation of a preparation for preventing and / or treating radiation-induced lung injury, and belongs to the technical field of medicines. The invention provides application of amlexanox combined with polydatin in preparation of a medicine for preventing and / or treating radiation-induced lung injury. The amlexanox and the polydatin are combined for use, so that the radiation-induced lung injury caused by ionizing radiation can be well prevented and / or treated, and the survival rate of a radiation-induced lung injury model mouse is increased by more than 50% on the premise of remarkably reducing the administration dosage of the amlexanox and the polydatin; the traditional Chinese medicine composition has the characteristics of small dosage, excellent prevention and / or treatment effect, no toxic or side effect and no dose dependence.

The application discloses a use of phenazine-1-carboxylic acid or a pharmaceutically acceptable salt thereof in preparation of a medicine for inhibiting African swine fever virus. The application uses a double reporter virus rASFV-Gluc / EGFP co-expressing green fluorescent protein and Gaussia luciferase to screen 246 natural small molecule compounds, and finds that phenazine-1-carboxylic acid has a significant inhibiting effect on replication of the ASFV; further evaluation of the inhibiting effect finds that the half maximal cytotoxicity concentration of PCA on target cells of primary porcine alveolar macrophages is 470.5 muM, and the half maximal inhibitory concentration of PCA on the ASFV in PAMs is 1.59 muM. According to a dose-dependent inhibiting experiment result, when the concentration of PCA is 25 muM, the inhibiting effect on the ASFV can reach more than 100 times. The application has application prospects in preparation of medicines or preparations against the ASFV.

The invention relates to application of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium in preparation of anti-cancer drugs, and belongs to the technical field of medical application, the structure of (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium is as shown in the following formula I, the (E)-2-(4-(dimethylamino) styryl)-6-methoxy-3-methylbenzo [d] thiazole-3-onium can inhibit the growth of gastric cancer cells, inhibit the proliferation, invasion and migration of the gastric cancer cells by promoting the autophagy and mitochondrial rupture of AGS and HGC-27 cells of the gastric cancer cells, and block the gastric cancer cells in the G1 stage. Furthermore, in-vivo experiments of mice prove that ZWK-3 can inhibit tumor growth of the mice, shows obvious dose dependence, and does not influence the body weight and visceral indexes of the mice at the same time. Formula I.

The application discloses a kind of benzofused heterocyclic ring amine pyrazolopyrimidine ketone derivatives, preparation method and application, belong to the technical field of pharmaceutical chemistry, the compound of the application has the structure shown in formula (I) or its pharmaceutically acceptable salt.The preparation method is with amino pyrazole as starting material, cyclization, chlorination, selective hydrolysis is prepared pyrazolopyrimidine ketone nucleus, again, the target compound is obtained by nucleophilic substitution reaction with benzofused heterocyclic ring substituted cyclic amine side chain of nucleus, simple operation, suitable for industrial production.The in vitro activity evaluation result shows that compound can significantly inhibit TGF-β1 induced hepatic stellate cell activation, effectively down-regulate the expression of fibronectin and collagen type I;Animal in vivo pharmacodynamics experiment further confirms that representative compound can dose-dependently reduce the degree of CCl4 induced mouse liver fibrosis, reduce collagen deposition, improve liver tissue pathological damage after oral administration (I).

This application discloses the application of dasabuvir as a TRPV4 inhibitor in improving diseases caused by increased TRPV4 expression or enhanced activity, particularly ulcerative colitis. Specifically, it relates to the biomedical field. Dasabuvir is a novel TRPV4 inhibitor that can improve symptoms in a DSS-induced mouse ulcerative colitis model and is suitable for use in TRPV4 inhibitor drugs and ulcerative colitis drugs. In HEK-293 cells overexpressing TRPV4, dasabuvir can dose-dependently inhibit the increase in intracellular calcium ion concentration induced by the TRPV4-specific agonist GSK1016790A within a concentration range of 0.03-30 μM, with an IC50 concentration of [missing information]. 50 At a concentration of 0.27 μM, Dasabuvir is a highly active TRPV4 inhibitor. In a DSS-induced ulcerative colitis model, Dasabuvir can improve weight loss, reduce the disease activity index, alleviate colonic shortening, reduce histopathological changes, and inhibit the expression of inflammatory factors, thus improving ulcerative colitis.

This invention discloses a heterozygous sesquiterpene tricyclic epoxy compound derived from the strain *Arthrum oligosporum*, its preparation method, and its applications, belonging to the field of natural product chemistry. This invention provides a heterozygous sesquiterpene tricyclic epoxy compound derived from *Arthrum oligosporum* (… A.oligospora ) AOL_ s00210g57 Anthrobotrisin D, a novel heterozygous sesquiterpene tricyclic epoxy compound from a gene knockout strain, has been shown in vitro to possess excellent anti-inflammatory activity, significantly inhibiting lipopolysaccharide-induced inflammatory responses in mouse microglia. It exhibits a clear dose-dependent inhibitory trend at multiple levels, including NO release, protein and mRNA expression of inflammatory factors (TNF-α, IL-1β, IL-6), and iNOS protein and mRNA expression. Furthermore, at a concentration of 33 μM, its anti-inflammatory effect is comparable to that of the clinically proven positive drug dexamethasone, and in some aspects, it is even superior. This invention not only provides a new lead compound for the development of anti-inflammatory drugs but also opens up new directions for developing new drugs from the unique microbial resource of nematode-preying fungi.

The invention discloses an application of distension hippocampus submicron powder in preparation of a composition for acetaminophen-induced liver injury. The application of the superfine powder form of the hippocampus japonicus which can be cultured on a large scale to the APAP liver injury is developed, the effect is equivalent to or superior to that of NAC, the advantages of dose dependence and multi-target protection are achieved, sustainable utilization of marine medicinal materials is promoted, and a novel, safe and effective strategy is provided for clinical prevention and treatment of the liver injury.

The invention discloses a nagilactone C liposome, a preparation method thereof and an application of the nagilactone C liposome in treatment of acute lung injury, conventional nagilactone C is prepared into the liposome with good solubility, and the liposome is used for treating the acute lung injury and has good anti-inflammatory activity. The liposome of the compound Nag C is prepared for the first time, it is found for the first time that the liposome of the compound Nag C can treat LPS-induced acute lung injury of mice, the Nagilactone C liposome can relieve inflammation-induced lung tissue cell apoptosis, and the protection effect shows obvious dose dependence.

The invention discloses ginseng polysaccharide GP40030-1 as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The ginseng polysaccharide GP40030-1 provided by the invention can obviously promote the proliferation of mouse macrophages RAW264.7 and effectively improve the phagocytic ability of cells, is dose-dependent in a concentration range of 12.5-100 mu g / mL, shows excellent immunomodulatory activity, and has a wide application prospect in the aspect of preparing medicines, functional foods or health products for enhancing immunity.

This invention discloses an endothelin A receptor antagonist-albumin fusion protein and its application in preventing and treating hypotension during anesthesia induction. The fusion protein is formed by chemically coupling BQ-123 with human serum albumin (HSA). BQFu significantly enhances its antihypertensive effect by prolonging the half-life of BQ-123 and improving plasma stability. Experiments show that BQFu dose-dependently inhibits the decrease in mean arterial pressure (MAP) in a propofol-induced hypotension model, with a sustained and stable effect in the high-dose group (30 mpk), shortening the recovery time to 20.8 ± 10.5 min, while maintaining BQ-123 activity. This invention provides a long-acting and safe prevention and treatment strategy for hypotension during anesthesia induction.

The application discloses application of a PRMT3 inhibitor SGC707 in preparation of a drug for treating pulmonary fibrosis, and for the first time verifies that a selective PRMT3 inhibitor SGC707 can dose-dependently inhibit expression of fibrosis markers such as COL1A1 and alpha-SMA in fibroblasts induced by TGF-beta 1 in vitro; in a bleomycin (BLM) induced mouse pulmonary fibrosis model, SGC707 administration can significantly improve lung tissue collagen deposition, reduce inflammatory cell infiltration, repair alveolar structure damage, and effectively down-regulate expression levels of fibrosis related proteins in lung tissues. It is proved that PRMT3 is a functional target with important intervention value in pulmonary fibrosis, SGC707 has definite anti-pulmonary fibrosis activity in vitro and in vivo, and a new drug strategy is provided for treatment of pulmonary fibrosis.

The Cardio-Tox Tissue Engineered Model (TEEM) invention provides a robust in vitro model for cardiotoxicity evaluation using three-dimensional (3D) human heart microtissues to quantify dose-dependent changes in electromechanical activity, resulting in a comprehensive cardiotoxicity and arrhythmia risk assessment of test compounds. The invention also provides a predictive in vitro screening platform for pro-arrhythmic toxicity testing using human three-dimensional cardiac microtissues. The invention enables the screening of environmental and pharmaceutical compounds, chemicals, and toxicants to establish safe human exposure levels.

The application provides a 5-hydroxymethylfurfural recognition aptamer and application, wherein the 5-hydroxymethylfurfural recognition aptamer comprises the following nucleotide sequence: 5'-GGGAGGACAGATACGGTGGGA-3'. The 5-hydroxymethylfurfural recognition aptamer provided by the application comprises good dose-dependent detection capability for 5-hydroxymethylfurfural, can rapidly realize accurate detection of 5-hydroxymethylfurfural in food, and has high detection convenience and does not need to rely on large and precise instruments.

The invention relates to cinacalcet hydrochloride, in particular to application of cinacalcet hydrochloride in preparation of drugs for treating allergic rhinitis. The invention discovers that cinacalcet hydrochloride has the effect of treating allergic rhinitis for the first time. Specifically, firstly, drugs capable of effectively inhibiting the NO release amount of RAW264.7 cells (using LPS to stimulate the RAW264.7 cells to establish an in-vitro inflammation model) are screened from 1430 small molecule compounds approved by FDA, and it is found for the first time that cinacalcet hydrochloride can inhibit NO release in the in-vitro inflammation model in a dose-dependent mode. On the other hand, in-vivo treatment experiments also find that cinacalcet hydrochloride can effectively inhibit release of allergic media in vivo without affecting the weight of mice, and has good safety.

The present invention discloses the application of deer horn glue in the treatment of zebrafish bone injury, belonging to the technical field of fish bone injury. The present invention prepared deer horn glue and used LPS induction to establish a zebrafish bone injury model for comprehensive evaluation. The IC50 of deer horn glue in zebrafish was 206.3 μg / mL; the treatment with deer horn glue could alleviate the inhibitory effects of LPS on cartilage development and bone formation in a dose-dependent manner; it could significantly reduce the green fluorescence intensity of macrophages and inhibit the activation of macrophages induced by LPS; it inhibited the excessive secretion of inflammatory factors IL-6, IL-1β and NO; it significantly restored the mRNA levels of bone-related genes COL2α1 and Sox9a. This study confirmed that deer horn glue could alleviate zebrafish bone injury caused by LPS and at the same time inhibit the macrophage-mediated inflammatory cascade reaction, providing a basis for the treatment of fish bone diseases.

The invention discloses application of physcion in preparation of a medicine for reducing liver cell lipid deposition, and particularly relates to application of physcion in preparation of a medicine for preventing and treating lipid deposition fatty liver. In-vitro cell experiments prove that the physcion shows low toxicity and a wide safety range in a human normal hepatocyte line THLE3, a human hepatoma cell line HepG2 and a mouse normal hepatocyte line AML12, and can obviously reduce the level of oleic acid-induced intracellular triglyceride in a dose-dependent manner, so that the physcion can be used for preparing a medicine for treating liver cancer. Oil red O staining results also visually show that lipid droplet accumulation in cells can be effectively reduced; according to the invention, the technical prejudice that the emodin monomethyl ether is regarded as a potential hepatotoxic component in the prior art is overcome, a safe and effective new choice is provided for the treatment of the lipid deposition fatty liver, and the pharmaceutical composition has a wide clinical application prospect.

The present invention discloses a semicarbazide derivative and its preparation method and application, which belongs to the technical field of anti-lung cancer targeted drugs. The semicarbazide derivative of the present invention can inhibit the growth of H1299 cells in a dose-dependent manner, but has little toxicity to normal lung epithelial cells BEAS-2B. The semicarbazide derivative of the present invention can significantly inhibit the cloning of non-small cell lung cancer cells A549 and H1299, so it has a significant inhibitory effect on the proliferation of non-small cell lung cancer. The semicarbazide derivative provided by the present invention can inhibit the protein expression of GPX4 in non-small cell lung cancer A549 cells, and by inhibiting the protein expression of GPX4, promote the ferroptosis of non-small cell lung cancer cells, thereby playing a role in suppressing tumors.

The invention discloses an indole diketopiperazine alkaloid compound as well as a preparation method and application of the indole diketopiperazine alkaloid compound. Aspergillus sp. SYPHU504 is preserved in Guangdong Microbial Culture Collection Center on August 26, 2024, and the preservation number is GDMCC No: 65055. According to the invention, the indole diketopiperazine alkaloid compound and the pharmaceutically acceptable salt, isomer or solvate of the indole diketopiperazine alkaloid compound are separated and prepared from a fermentation culture of Aspergillus sp. SYPHU504. It is found through tests that the indole diketopiperazine alkaloid compound can remarkably inhibit proliferation of leukemia cell strains K562 and RS4: 11, and dose dependence is shown. Therefore, the compound is expected to be developed into a safe and effective novel anti-leukemia drug, and has important significance on development of Chinese marine drug resources.